Oramed Pharmaceuticals Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report. Dollar amounts below are U.S. dollars; financial statement amounts are generally shown in millions.
Business context
Oramed is a development-stage pharmaceutical company focused on oral delivery of insulin and other therapeutic proteins. It has no product revenue and relies on licensing revenue and financing. In 2023, it terminated two Phase 3 oral-insulin trials after the lead trial failed its primary and secondary endpoints. It is analyzing selected patient subgroups and preparing a protocol for a possible new Phase 3 trial.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $1.34 million | $2.70 million |
| Research and development expense | $8.97 million | $27.64 million |
| General and administrative expense | $8.43 million | $13.81 million |
| Operating loss | $15.77 million | $40.60 million |
| Net income (loss) | $5.09 million | ($37.76 million) |
| Operating cash used | $10.30 million | $27.92 million |
- Net income in 2023 included substantial financial income, including a reported $15.64 million gain from revaluing Scilex-related investments; it does not indicate operating profitability. Revenue was licensing-related, and cost of revenue was zero in both years, so conventional product margins are not meaningful.
- Cash and cash equivalents were $9.06 million and short-term deposits were $95.28 million at year-end. Working capital was $109.37 million, down from $151.36 million in 2022.
- Current liabilities included $51.01 million of short-term bank borrowings, of which $49.55 million remained due in 2024. The borrowings were secured by bank certificates of deposit.
- Scilex-related amounts are investments/receivables held by Oramed, not Oramed debt: the Scilex Note had a year-end fair value of $93.07 million, alongside warrants. Fair value of the total Scilex transaction instruments was reported as $110.19 million. The Note is secured, bears interest at Term SOFR plus 8.5%, and matures March 21, 2025; Oramed received the first $5 million principal payment in December 2023.
- Cash decreased by $31.41 million during 2023. Operating activities used $10.30 million, investing activities used $73.04 million, and financing activities provided $51.98 million.
Material changes and notable items
- Revenue fell 50%, primarily because recognition of HTIT-related revenue ended at the expected product-submission date in June 2023. R&D expense declined 68%, mainly following termination of the Phase 3 trials; lower stock compensation also reduced R&D and G&A expense.
- Oramed completed the Scilex transaction in September 2023, converting a $100 million debtor-in-possession loan arrangement into a secured Scilex Note and warrants. The Note and warrants are measured at fair value, with estimates dependent on repayment scenarios and other significant assumptions.
- In January 2024, Oramed signed a conditional joint venture agreement with HTIT. The proposed JV would be 50/50 initially; HTIT would contribute $70 million and Oramed $20 million, plus specified intellectual property and other assets. Oramed would receive a 3% royalty on gross revenue from Oramed-related assets. Closing depends on additional agreements and other conditions and is not assured.
- Oramed acquired PeriTech topical-delivery technology in December 2023 and licensed the pipeline to Genomma Labs for royalties based on net sales.
Outlook, risks and contingencies
- Management said existing cash resources and commitments should support planned activity for at least 12 months, but warned that additional financing may be needed sooner if costs rise or to implement strategic plans. Oramed expects R&D to be a major expense if it proceeds with a new trial; the proposed JV could bear trial costs if completed.
- The company is evaluating strategic alternatives, with no assurance that a transaction or other plan will be pursued or completed. It also faces ongoing losses, limited revenue, clinical and regulatory uncertainty, and potential dilution from future financing.
- Scilex has disclosed substantial doubt about its ability to continue as a going concern. Oramed warns that it may not recover the Note in full or realize value from the warrants; the valuation is a critical audit matter and depends on significant assumptions.
- HTIT disputes payment obligations estimated by Oramed at $2 million to $6 million. If unresolved, Oramed may have to repay up to $2 million already received and could forgo an additional $4 million in royalties.
- Other disclosed risks include execution and governance of the proposed JV, dependence on third-party suppliers and partners, Israeli security and currency risks, and possible volatility or dilution in Oramed’s stock. The filing reports no material legal proceedings currently pending. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an ICFR opinion.
Important facts for investors to verify
- Whether the FDA accepts a new Phase 3 protocol, and whether the subgroup findings from the failed trial can be replicated prospectively.
- Whether the HTIT JV’s required agreements and closing conditions are completed, and how the proposed contributions, asset transfers, funding, and trial costs are ultimately implemented.
- Scilex’s ability to meet scheduled Note payments, the value and enforceability of collateral, and the assumptions underlying Oramed’s fair-value estimates.
- Remaining 2024 bank-borrowing maturities, cash use, and any need for additional financing or equity issuance.
- Resolution of the HTIT payment dispute and the status of Medicox’s Korean regulatory and commercialization efforts.